GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptose Biosciences Inc (NAS:APTO) » Definitions » EPS (Diluted)

Aptose Biosciences (Aptose Biosciences) EPS (Diluted) : $-6.20 (TTM As of Mar. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Aptose Biosciences EPS (Diluted)?

Aptose Biosciences's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.73. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.20.

Aptose Biosciences's EPS (Basic) for the three months ended in Mar. 2024 was $-0.73. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.20.

Aptose Biosciences's EPS without NRI for the three months ended in Mar. 2024 was $-0.73. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.20.

During the past 3 years, the average EPS without NRIGrowth Rate was 7.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 7.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Aptose Biosciences's highest 3-Year average EPS without NRI Growth Rate was 42.50% per year. The lowest was -18.20% per year. And the median was 11.70% per year.


Aptose Biosciences EPS (Diluted) Historical Data

The historical data trend for Aptose Biosciences's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptose Biosciences EPS (Diluted) Chart

Aptose Biosciences Annual Data
Trend May14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.80 -10.05 -10.95 -6.80 -7.58

Aptose Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.22 -2.27 -1.76 -1.44 -0.73

Competitive Comparison of Aptose Biosciences's EPS (Diluted)

For the Biotechnology subindustry, Aptose Biosciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptose Biosciences's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptose Biosciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Aptose Biosciences's PE Ratio falls into.



Aptose Biosciences EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Aptose Biosciences's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-51.207-0)/6.755
=-7.58

Aptose Biosciences's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-9.64-0)/13.133
=-0.73

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptose Biosciences  (NAS:APTO) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Aptose Biosciences EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Aptose Biosciences's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptose Biosciences (Aptose Biosciences) Business Description

Traded in Other Exchanges
Address
251 Consumers Road, Suite 1105, Toronto, ON, CAN, M2J 4R3
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Executives
Bernd R. Seizinger director 535 BOYLSTON STREET, BOSTON MA 02116
William G. Rice director, officer: Chair, President & CEO C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Fletcher Payne officer: SR VP & Chief Fin. Officer 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Philippe Ledru officer: Chief Commercial Officer C/O APTOSE BIOSCIENCES INC., 2511 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Denis R Burger director CYTODYN INC., 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Erich Platzer director
Rafael Bejar officer: Chief Medical Officer C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Wilson Donald R. Jr. 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Holdings, Llc 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Commodities, Llc 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Warren Whitehead director C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Gregory K. Chow officer: Senior VP & CFO C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Jotin Marango officer: Senior VP, Chief Bus. Officer C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Mark D. Vincent director C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3